Finding Intent Signals in B2B Life Sciences Account-Based Marketing

Intent data is one of the most powerful concepts in modern B2B marketing. The idea is straightforward: if you can identify which companies are actively researching a problem your solution solves, you can focus your commercial resources on those accounts at precisely the moment they are most likely to buy. Done well, it transforms prospecting from an exercise in educated guessing into something far more precise. This targeted marketing is a core concept of account-based marketing (ABM.)

The challenge for life science companies is that the intent data infrastructure built to support ABM programs was designed firstly for the B2B technology sector. The signals it captures, the databases it monitors, and the models it uses to score account intent are calibrated for software buyers and not for the biotech, pharma, and research institutions that make up the life science market. For organizations in this sector, adopting standard ABM intent tooling without adaptation can lead to a program that is technically sophisticated but commercially misaligned. The program may end up surfacing the wrong accounts, miss the right ones, and generate noise rather than actionable information.

This post explains what genuine intent looks like in B2B life sciences, why standard ABM platforms are limited in capturing it, and how to build an intent intelligence approach that reflects the actual dynamics of this market.

What Standard ABM Intent Data Actually Measures

To understand why standard intent tools underperform in life sciences, it helps to understand what they are actually measuring.

Platforms that focus on intent data like Bombora and 6Sense build their intent models primarily around two types of signal. The first is keyword-based web activity: elevated volumes of search queries and content consumption around specific topics, detected through publisher networks, content partnerships, and search engine data. When an unusual number of employees at a company are searching for potentially relevant search terms, the platform flags that company as showing elevated intent.

In life sciences, the limitation of keyword-based intent is granularity. Monitor a broad technical term like a specific assay type, and the data conflates scientists looking for protocol guidance with stakeholders preparing to outsource the work. The result is a mix of false positives and missed opportunities: the signal that matters is more specific than what generic keyword models are built to capture.

The second type of intent data is behavioral pattern matching: tracking when company employees visit competitor websites, engage with industry analyst reports, or interact with solution-category content in ways that suggest an active evaluation is underway.

These signals are genuinely useful in the B2B technology market, where buyers research solutions primarily through web searches, vendor websites, and analyst coverage before initiating contact. When a team is evaluating a new CRM, they search, they compare, they read G2 reviews, and they visit vendor sites. That behavior is detectable and meaningful.

In life sciences, this behavioral pattern either does not exist in the same form, or when it does, it is a lagging indicator rather than a leading one. A biotech that has already decided to outsource its Phase 2 biomarker program and is now requesting proposals is generating keyword intent signals. But by the time those signals are detectable, the evaluation is likely already underway and the vendor shortlist may already be forming. The most valuable moment to reach that account was weeks or months earlier, when the decision to advance the program was made but the vendor selection process had not yet begun.

Standard ABM tools are not designed to surface that earlier signal. They are designed to detect the footprint of an active search which in life sciences may arrive too late to act on meaningfully.

What Genuine Intent Looks Like in Life Sciences

The most predictive intent signals in B2B life sciences are not behavioral patterns detected through web monitoring. They are discoverable events: publicly documented milestones in a company's scientific, clinical, and financial development. These are the signals that predict the upcoming vendor needs the company is likely to have.

Clinical trial registrations and IND filings are among the most valuable signals available. A new ClinicalTrials.gov registration indicates that a specific program has been designed, approved for execution, and is preparing to enroll. An IND submission signals that a company is preparing to advance an asset into first-in-human studies. These events create immediate and specific purchasing needs: clinical operations support, central laboratory services, bioanalytical and biomarker capabilities, regulatory affairs support, etc. The program is defined, the timeline is beginning, and there will be purchasing needs. Vendors who identify this signal early and proactively engage the relevant personas early have a meaningful advantage over those who wait to be invited through an RFP.

Funding events: Series B, C, and D rounds, IPOs, and significant non-dilutive funding such as BARDA contracts or large NIH grants are direct predictors of program acceleration and vendor investment. Funding does not just provide capital; it creates organizational pressure to deploy that capital productively and to demonstrate progress against the milestones used to justify the raise. The months that follow a significant raise tend to be periods of program investment and vendor engagement. A company that raised a $120M Series C to advance two assets into Phase 2 is an account to engage immediately and deliberately.

Certain Regulatory milestones can compress timelines and create urgency. A Fast Track designation, a Breakthrough Therapy designation, an Orphan Drug designation, or a Priority Review designation all signal that the FDA has recognized the potential significance of an asset and is providing mechanisms to accelerate its development. For vendors serving the clinical development pipeline, these designations are a direct signal that the program in question is being resourced and accelerated and that the buying group associated with it is likely to make decisions faster than a standard development timeline would suggest.

Pipeline advancement events include a company announcing positive Phase 1 data, a transition from preclinical to IND-enabling studies, or a decision to advance an asset from Phase 2 into a pivotal trial. These each carry specific and predictable commercial implications. The services and technologies needed at Phase 2 are different from those needed at Phase 1, and the investment required for a pivotal trial is substantially larger. These transitions create new buying groups, new budget allocations, and new vendor needs that did not exist at the prior stage.

Partnerships, licensing deals, and acquisitions can signal both program advancement and organizational transformation. A licensing deal that brings a new asset into a company's pipeline creates immediate needs around program support infrastructure. An acquisition can introduce new therapeutic capabilities and create demand for the vendor relationships needed to support them. Large co-development partnerships with major pharma often trigger significant investment in outsourced services to support the partnered program.

For academic and government research targets, grant awards are the equivalent signals. These can be tracked through sources like NIH Reporter, BARDA contract awards, or DOD funding announcements. A new R01 award to a research group working in a relevant therapeutic area is a direct indicator of funded research activity and the instrument and reagent purchasing that may follow.

Why a Layered Intelligence Approach Outperforms Single-Source Intent

The strongest life science ABM programs do not rely on a single source of intent intelligence. They layer multiple signal types to create a picture of in-market accounts that is both strategically grounded and behaviorally confirmed.

The foundation layer is the public events described above: clinical trial filings, funding rounds, regulatory designations, pipeline transitions. These signals establish that an account has a documentable reason to be in market. They can be sourced through dedicated life-science data platforms like BCIQ, GlobalData, etc., or can bepulled and merged from public clinical trial registries, company website data, SEC and regulatory filing databases, and grant award databases. But these key signals won't be found using standard ABM or intent platforms.

The second layer is keyword-based behavioral intent, which can be sourced from standard intent or ABM platforms. While this signal type is less predictive in isolation for life science accounts, it remains useful as a corroborating indicator. An account that has recently filed a new IND and shows elevated web activity around relevant search terms is a stronger signal. When event-driven and behavioral intent converge on the same account, the probability of active buying-cycle engagement is higher.

The third layer is first-party engagement data from your own campaigns: website visits, content downloads, webinar registrations, ad interactions, and email engagement. An account that appears in your event-driven intent data, while also showing behavioral intent signals in the broader web environment, and has had multiple individuals engage with your own content is an account which should almost certainly be prioritized for sales or BD outreach.

From Intent Signal to Commercial Action

Overall, the process is:

1. Use the right life science intent data to find companies who match the ICP for your marketing program
2. Get in front of them with relevant messaging
3. Merge keyword-based intent data and first-party engagement data (including ABM program data) to surface the strongest candidates for the sales team
4. Hand those accounts over to the SDR or BD team for outreach
5. Regularly refresh your target list to find new companies showing intent that matches your ICP

Identifying intent signals is only the first step. The commercial value is realized in how quickly and precisely the organization responds to them.

The speed of response matters more in life sciences than most commercial teams appreciate. Buying groups form, make shortlists, and issue RFPs on timelines driven by their program milestones, not by the vendor's campaign calendar. An organization that identifies the intent signal and engages within the first week of a new clinical trial filing is having a different conversation than one that engages two months later when the RFP has already been issued. The window of maximum commercial advantage is real but it closes.

The best targeted marketing programs set up their approach to use the right mix of tools and data to get in front of the right accounts with relevant messages. And, importantly, the best ABM programs regularly refresh their target list to ensure any new companies that fit their ICP are targeted.

A life science ABM program built on the right intent intelligence produces better targeting and the ability to act at the right moment, with the right message, to the right people before the buying process has already decided who is in the room and ultimately sets their BD team up for success and more won business.